NEW YORK, April 9 – Spotfire said Monday that it has signed agreements with both Celera and Biogen for use of Spotfire’s DecisionSite analytical software.
Celera and Spotfire will integrate DecisionSite, which enables visual analysis of product, process, and customer information from a variety of sources, with the Celera Discovery System, which provides access to Celera’s human, mouse, and fly genomes as well as other biological databases.
Users will be able to move between DecisionSite and CDS in order to add genomic and biomedical information from CDS to their own data and experiment results.
Biogen has licensed DecisionSite to help its researchers access, analyze, and share data and collaborate across teams, departments, and geographies in the drug discovery and development process.
Financial terms of the agreements were not disclosed.
"We recognize that one of the key next challenges in the genome race is to equip decision makers with an integrated user experience into genomics , chemistry, and screening data. Spotfire DecisionSite gives us this ability, resulting in a substantial competitive advantage," said Rainer Fuchs, senior director of research informatics at Biogen, in a statement.